Navigation Links
Oral contraceptives impair muscle gains in young women
Date:4/17/2009

NEW ORLEANSMany active young women use oral contraceptives (OC) yet its effect on their body composition and exercise performance has not been thoroughly studied. A team of researchers has now examined the effects of OC on female muscle mass, and found that oral contraceptive use impairs muscle gains in young women, and is associated with lower hormone levels.

The findings are contained in a new study entitled Oral Contraceptive Use Impairs Muscle Gains in Young Women. It was conducted by Chang-Woock Lee and Steven E. Riechman, Department of Health and Kinesiology, Texas A&M University, College Station, TX; and Mark A. Newman, Human Energy Research Laboratory, University of Pittsburgh, Pittsburgh, PA. The researchers will present their findings at the 122nd Annual Meeting of the American Physiological Society (APS; www.the-aps.org/press), which is part of the Experimental Biology 2009 scientific conference. The meeting will be held April 18-22, 2009 in New Orleans.

The Study

Seventy-three generally healthy women between the ages of 18-31 were assigned to two groups and completed a 10-week whole-body resistance exercise training (RET). Group 1 consisted of 34 women who used oral contraceptives (OC). Group 2 consisted of 39 women who did not take birth control pills (non-OC). The women were encouraged to consume at least 0.5 grams of protein per pound of body weight per day (a third more than is called for by the U.S. government nutritional guidelines) to make sure they consumed enough calories and protein to promote muscle growth.

The participants exercised three times per week for ten weeks under the supervision of exercise physiologists. They performed a variety of exercises to include chest press, lat pull down, leg extension, triceps extension, arm curl and abdominal crunch. Exercise was done using standard exercise machines and each volunteer performed three sets of 6-10 repetitions per exercise at 75 percent of their maximum strength. Body composition was determined using hydrostatic weighing.

Blood samples were taken before and after the training and assessed to measure anabolic (muscle building) and catabolic (muscle breaking) hormone levels in blood. Resting and fasting blood concentrations were measured for three anabolic hormones: DHEA, DHEAS and IGF1.

Findings

The researchers found that:

  • there were significant differences in lean mass gains (OC: 2.12.1% vs. non-OC: 3.53.2% / OC: 1.01.0kg vs. no-OC: 1.61.4kg, p< 0.05). However, other muscle responses such as strength gains and arm/leg circumferences were similar between the OC and non-OC users.

  • resting/fasting blood concentrations of the anabolic hormones were significantly lower in women taking OC vs. non-OC users throughout the study period. At the same time, plasma concentrations of cortisol (catabolic hormone) were elevated.

  • those OC users had reduced DHEA hormone at the end of the training period. By contrast, the other participants' levels did not change.

Conclusion

According to the researchers, "We were surprised at the magnitude of differences in muscle gains between the two groups, with the non-OC women gaining more than 60% greater muscle mass than their OC counterpart." They added that even though the study has observed negative effects of oral contraceptive use on muscle gain in the context of resistance exercise training, "future studies are needed to help explain the reasons behind the results."


'/>"/>

Contact: Donna Krupa
dkrupa@the-aps.org
703-967-2751
American Physiological Society
Source:Eurekalert

Related biology news :

1. Texas A&M testing oral contraceptives for animals
2. Continuous oral contraceptives better at easing pain, bleeding
3. Oral contraceptives impair muscle gains in young women
4. Low oxygen in coastal waters impairs fish reproduction
5. Extended wakefulness, combined with alcohol, severely impairs driving performance
6. Breathless babies: Preemies lung function shows prolonged impairment
7. Early exposure to common weed killer impairs amphibian development
8. Telescope embedded in glasses lens promises to make driving easier for visually impaired
9. Chronic exposure to estrogen impairs some cognitive functions
10. Scientists identify cell changes leading to impaired artificial kidney function
11. Understanding how oxidative stress impairs endothelial progenitor cell function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: